Clinical Trial Update: A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . . [Phase 2]

View source ↗

Summary

A Phase 2 pilot study evaluating neoadjuvant chemoradiotherapy with capecitabine for pancreatic cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Xeloda (capecitabine)

Snippet

Sponsor: University of Massachusetts, Worcester | Conditions: Pancreatic Cancer | Phase 2 | Status: WITHDRAWN